NUVL
Price
$94.68
Change
-$2.35 (-2.42%)
Updated
Nov 13 closing price
Capitalization
6.88B
110 days until earnings call
Intraday BUY SELL Signals
ORIC
Price
$12.19
Change
-$0.29 (-2.32%)
Updated
Nov 13 closing price
Capitalization
1.18B
130 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NUVL vs ORIC

Header iconNUVL vs ORIC Comparison
Open Charts NUVL vs ORICBanner chart's image
Nuvalent
Price$94.68
Change-$2.35 (-2.42%)
Volume$323.37K
Capitalization6.88B
Oric Pharmaceuticals
Price$12.19
Change-$0.29 (-2.32%)
Volume$708.27K
Capitalization1.18B
NUVL vs ORIC Comparison Chart in %
NUVL
Daily Signal:
Gain/Loss:
ORIC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NUVL vs. ORIC commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Hold and ORIC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (NUVL: $97.03 vs. ORIC: $12.48)
Brand notoriety: NUVL and ORIC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 61% vs. ORIC: 63%
Market capitalization -- NUVL: $6.88B vs. ORIC: $1.18B
NUVL [@Biotechnology] is valued at $6.88B. ORIC’s [@Biotechnology] market capitalization is $1.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whileORIC’s FA Score has 1 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • ORIC’s FA Score: 1 green, 4 red.
According to our system of comparison, both NUVL and ORIC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 3 TA indicator(s) are bullish while ORIC’s TA Score has 2 bullish TA indicator(s).

  • NUVL’s TA Score: 3 bullish, 5 bearish.
  • ORIC’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, both NUVL and ORIC are a bad buy in the short-term.

Price Growth

NUVL (@Biotechnology) experienced а +5.36% price change this week, while ORIC (@Biotechnology) price change was +0.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

ORIC is expected to report earnings on Mar 24, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($6.88B) has a higher market cap than ORIC($1.18B). ORIC YTD gains are higher at: 54.647 vs. NUVL (23.952). ORIC has higher annual earnings (EBITDA): -148.48M vs. NUVL (-362.01M). NUVL has more cash in the bank: 1.01B vs. ORIC (283M). NUVL (0) and ORIC (0) have equivalent revenues.
NUVLORICNUVL / ORIC
Capitalization6.88B1.18B581%
EBITDA-362.01M-148.48M244%
Gain YTD23.95254.64744%
P/E RatioN/AN/A-
Revenue00-
Total Cash1.01B283M355%
Total DebtN/A3.27M-
TECHNICAL ANALYSIS
Technical Analysis
NUVLORIC
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signal:
Gain/Loss:
ORIC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MWEHX47.960.20
+0.42%
MFS Global Equity R3
MRSPX15.920.02
+0.13%
BlackRock Advantage SMID Cap R
RYANX159.050.14
+0.09%
Rydex Nova A
RLSFX15.390.01
+0.07%
RiverPark Long/Short Opportunity Retail
FEQMX49.75N/A
N/A
Fidelity Advisor Emerging Markets M

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with RVMD. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+0.91%
RVMD - NUVL
62%
Loosely correlated
+2.73%
XENE - NUVL
61%
Loosely correlated
-0.60%
XNCR - NUVL
60%
Loosely correlated
-3.23%
IDYA - NUVL
59%
Loosely correlated
-0.19%
CGON - NUVL
58%
Loosely correlated
+1.47%
More

ORIC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORIC has been loosely correlated with ERAS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ORIC jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORIC
1D Price
Change %
ORIC100%
-3.11%
ERAS - ORIC
48%
Loosely correlated
+12.29%
NRIX - ORIC
46%
Loosely correlated
-5.37%
KYMR - ORIC
46%
Loosely correlated
+0.25%
NUVL - ORIC
45%
Loosely correlated
+0.91%
ELVN - ORIC
45%
Loosely correlated
+3.36%
More